Ascentage Pharma Group International
OTC:ASPHF
Ascentage Pharma Group International
OTC:ASPHF
Price:
8.48
USD
Market Closed
Market Cap:
$2.7B
Income Statement
Earnings Waterfall
Ascentage Pharma Group International
Ascentage Pharma Group International
Income Statement
Ascentage Pharma Group International
Ascentage Pharma Group International
Currency: CNY
| Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Interest Expense |
4
|
0
|
6
|
0
|
17
|
0
|
53
|
0
|
96
|
0
|
64
|
0
|
|
| Revenue |
15
N/A
|
15
+2%
|
12
-16%
|
23
+83%
|
28
+22%
|
111
+297%
|
210
+89%
|
257
+22%
|
222
-14%
|
903
+307%
|
981
+9%
|
391
-60%
|
|
| Gross Profit | |||||||||||||
| Cost of Revenue |
(2)
|
0
|
(2)
|
(5)
|
(3)
|
(6)
|
(22)
|
(35)
|
(31)
|
(27)
|
(29)
|
(36)
|
|
| Gross Profit |
12
N/A
|
0
N/A
|
10
N/A
|
18
+74%
|
25
+35%
|
105
+327%
|
188
+79%
|
222
+18%
|
191
-14%
|
876
+357%
|
952
+9%
|
355
-63%
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(1 473)
|
(1 198)
|
(698)
|
(756)
|
(918)
|
(1 059)
|
(1 041)
|
(1 036)
|
(1 065)
|
(1 206)
|
(1 326)
|
(1 508)
|
|
| Selling, General & Administrative |
(162)
|
(162)
|
(130)
|
(143)
|
(191)
|
(270)
|
(328)
|
(349)
|
(376)
|
(353)
|
(332)
|
(393)
|
|
| Research & Development |
(464)
|
(516)
|
(565)
|
(631)
|
(766)
|
(790)
|
(743)
|
(712)
|
(707)
|
(824)
|
(914)
|
(1 002)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(43)
|
(85)
|
(80)
|
|
| Other Operating Expenses |
(848)
|
(520)
|
(3)
|
18
|
40
|
2
|
30
|
25
|
18
|
14
|
5
|
(32)
|
|
| Operating Income |
(1 461)
N/A
|
(1 183)
+19%
|
(688)
+42%
|
(737)
-7%
|
(893)
-21%
|
(954)
-7%
|
(853)
+11%
|
(814)
+5%
|
(874)
-7%
|
(330)
+62%
|
(374)
-13%
|
(1 153)
-208%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
(22)
|
15
|
12
|
7
|
61
|
92
|
(36)
|
(70)
|
(59)
|
(40)
|
(21)
|
9
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
(0)
|
0
|
0
|
(0)
|
0
|
|
| Pre-Tax Income |
(1 482)
N/A
|
(1 168)
+21%
|
(675)
+42%
|
(730)
-8%
|
(832)
-14%
|
(860)
-3%
|
(887)
-3%
|
(885)
+0%
|
(933)
-5%
|
(370)
+60%
|
(395)
-7%
|
(1 143)
-189%
|
|
| Net Income | |||||||||||||
| Tax Provision |
2
|
2
|
(2)
|
(5)
|
50
|
48
|
4
|
6
|
7
|
10
|
(10)
|
(16)
|
|
| Income from Continuing Operations |
(1 481)
|
(1 167)
|
(678)
|
(735)
|
(782)
|
(812)
|
(883)
|
(879)
|
(926)
|
(361)
|
(406)
|
(1 159)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(1 481)
N/A
|
(1 167)
+21%
|
(678)
+42%
|
(735)
-8%
|
(782)
-6%
|
(812)
-4%
|
(883)
-9%
|
(879)
+0%
|
(926)
-5%
|
(360)
+61%
|
(405)
-13%
|
(1 159)
-186%
|
|
| EPS (Diluted) |
-12.69
N/A
|
-5.58
+56%
|
-3.14
+44%
|
-2.97
+5%
|
-3.07
-3%
|
-3.09
-1%
|
-3.35
-8%
|
-3.19
+5%
|
-3.28
-3%
|
-1.25
+62%
|
-1.34
-7%
|
-3.39
-153%
|
|
Switch to:
Switch to:
See Also
Discover More
